Filter Releases
 
Press Releases
Date Title and Summary View
Feb 1, 2017
— Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned to alendronate in ACTIVExtend show statistically significant reductions at six months in the incidence of new vert...
Jan 31, 2017
WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2016 financial results on Thursday, February 23, 2017.In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 4:30 p.m. ET on Thurs...
Jan 6, 2017
WALTHAM, Mass., Jan. 06, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annua...
Dec 8, 2016
 -3 patients had confirmed partial responses by RECIST criteria from ongoing Phase I studies with RAD1901 in patients with advanced estrogen receptor positive breast cancer- -In the Phase 1 dose escalation and expansion study, 14 heavily pretreated patients remained on RAD1901 for equal t...
Nov 3, 2016
ACTIVE Phase 3 trial results published in Journal of American Medical Association and Journal of Bone Mineral ResearchRadius to present three abstracts on RAD1901 at San Antonio Breast Cancer Symposium in DecemberWALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Radi...
Nov 1, 2016
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the ...
Oct 12, 2016
WALTHAM, Mass., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its third quarter 2016 financial results on Thursday, November 3, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Thur...
Sep 19, 2016
-Second Generation Transdermal Patch Achieves Pharmacokinetic Objectives— WALTHAM, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Radius Health Inc. (Nasdaq:RDUS) a science-driven biopharmaceutical company committed to developing innovative therapeutics in the areas of osteoporosis, onc...
Sep 18, 2016
WALTHAM, Mass., Sept. 18, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that additional positive results from the Phase 3 ACTIVE (...
Aug 30, 2016
WALTHAM, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of RAD1901, ...
Aug 16, 2016
WALTHAM, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and other endocrine diseases, today announced that positive results from the Phase 3 ACTIVE (...
Aug 4, 2016
Radius' NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis was accepted for filing by FDA with a PDUFA date of March 30, 2017 An oral presentation on the clinical development progress of an optimized abaloparatide transdermal patch has been acce...
Aug 2, 2016
WALTHAM, Mass., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis, hormone responsive metastatic breast cancer, and other postmenopausal conditions including vasomotor symptoms, today announced that President an...
Jul 20, 2016
WALTHAM, Mass., July 20, 2016 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced today that it will present new data from multiple studies of abaloparatide ...
Jul 15, 2016
WALTHAM, Mass., July 15, 2016 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS) announced today that it will release its second quarter 2016 financial results on Thursday, August 4, 2016. In connection with the earnings release, Radius Health will host a conference call and live audio webcast at 8:00 a.m. ET on Th...
Page:
...
Next Last
 
= add release to Briefcase